Dai Nan, Su Xiaorong, Wang Yong
Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Diabetes Obes Metab. 2025 Jan;27(1):377-386. doi: 10.1111/dom.16031. Epub 2024 Oct 30.
The purpose of this study is to explore the rational pricing range for the once-weekly administration of insulin icodec in the treatment of type 2 diabetes patients in China who have already received basal insulin therapy.
The data foundation of this study originates from the ONWARDS 4 clinical trial and research materials on Chinese type 2 diabetes patients. By comprehensively applying cost-utility analysis methods and binary search techniques, the appropriate price positioning of insulin icodec was determined from the perspective of China's healthcare system.
In the long-term treatment simulation, we found that insulin icodec and insulin glargine performed similarly in terms of quality-adjusted life years (QALYs), with 10.15 and 10.07 years, respectively. Although the annual cost of insulin icodec was initially assumed to be equivalent to that of insulin glargine, in-depth analysis revealed that insulin icodec may have higher cost-effectiveness potential. Further price sensitivity analysis indicated that the reasonable cost range of insulin icodec lies between $851.95 and $1358.25. After fine-tuning through univariate sensitivity analysis, this cost range was revised to $784.90 to $1145.96, a conclusion that was robustly validated in subsequent probabilistic sensitivity analysis and scenario simulations.
The conclusion drawn from this study is that, with insulin glargine as the cost reference, the economic cost of insulin icodec for Chinese type 2 diabetes patients is expected to range from $784.90 to $1145.96, providing a reference basis for clinical decision-making and healthcare policy formulation.
本研究旨在探索在中国已接受基础胰岛素治疗的2型糖尿病患者中，每周一次注射icodec胰岛素的合理定价范围。
本研究的数据基础源自ONWARDS 4临床试验及中国2型糖尿病患者的研究资料。通过综合应用成本-效用分析方法和二分搜索技术，从中国医疗体系的角度确定icodec胰岛素的合适价格定位。
在长期治疗模拟中，我们发现icodec胰岛素和甘精胰岛素在质量调整生命年（QALY）方面表现相似，分别为10.15年和10.07年。尽管最初假设icodec胰岛素的年成本与甘精胰岛素相当，但深入分析表明icodec胰岛素可能具有更高的成本效益潜力。进一步的价格敏感性分析表明，icodec胰岛素的合理成本范围在851.95美元至1358.25美元之间。通过单因素敏感性分析进行微调后，该成本范围修订为784.90美元至1145.96美元，这一结论在随后的概率敏感性分析和情景模拟中得到了有力验证。
本研究得出的结论是，以甘精胰岛素为成本参考，中国2型糖尿病患者使用icodec胰岛素的经济成本预计在784.90美元至1145.96美元之间，为临床决策和医疗政策制定提供了参考依据。
